Orient EuroPharma Co., Ltd.
4120
Rank in Stocks
#19208
Orient EuroPharma Co., Ltd. (OEP) operates as a global pharmaceutical... Orient EuroPharma Co., Ltd. (OEP) operates as a global pharmaceutical enterprise, engaged in the development and production of various medications. Its portfolio of prescription pharmaceuticals encompasses treatments for a wide array of conditions, such as cardiovascular issues, metabolic disorders, neurological ailments, obstetric and gynecological health, respiratory diseases, andrological concerns, immunological responses, as well as antibiotics and anti-cancer therapies. Beyond prescription drugs, the company offers nutritional and infant care items, including specialized milk formulas and dietary supplements, marketed under the brand names Karihome, Babecare, and Ostricare. Additionally, it supplies health-related supplements, notably Buccotherm-branded thermal water, designed for the management of oral and periodontal conditions. The company's diverse product range extends to skincare, featuring items like essences, creams, lotions, eye creams, facial toners, and skin-repairing treatments available through its AGLab line. It also distributes skincare oils, body lotions, and gels for dry skin under the well-known Bio-Oil brand, and markets children's skincare solutions through the Mister Baby brand. Furthermore, OEP oversees ISISPHARMA, a dermatology laboratory dedicated to the creation and distribution of specialized dermo-cosmetic goods. Orient EuroPharma is actively involved in extensive research and development efforts, with several key compounds in its pipeline. These include Multikine, an immunotherapy treatment for head and neck cancer currently undergoing Phase III clinical trials; NC-6004, a platinum-based micelle chemotherapeutic agent also in Phase III; ASC-J9, a molecular chemical entity targeting androgen receptor degradation, which has successfully finished its Phase IIb clinical study; and 2ccPA, a phospholipid derivative for symptomatic knee osteoarthritis, progressing through Phase I clinical trials. Established in 1982, Orient EuroPharma Co., Ltd. maintains its headquarters in Taipei, Taiwan.
Share Price
$1.29
Last synced: 2026-11-10
Market Cap
$111.86M
Change (1 day)
0.59%
Change (1 year)
-14.97%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Orient EuroPharma Co., Ltd. (4120)
Category
Healthcare
Operating Margin for Orient EuroPharma Co., Ltd. (4120)
Operating Margin as of November 2026 TTM: -7.36%
According to Orient EuroPharma Co., Ltd.'s latest financial reports, its current operating margin (TTM) is -7.36%. At the end of 2025 the company had an operating margin of -6.76%.
Operating Margin history for Orient EuroPharma Co., Ltd. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -7.36% | 8.88% |
| 2025 | -6.76% | -2,353.33% |
| 2024 | 0.30% | -83.70% |
| 2023 | 1.84% | -133.58% |
| 2022 | -5.48% | 352.89% |
| 2021 | -1.21% | -122.92% |
| 2020 | 5.28% | -4.35% |
| 2019 | 5.52% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -102.64% |
DE
|
|
| 19.68% | -102.67% |
DE
|
|
| 13.26% | -101.80% |
JP
|
|
| 17.08% | -102.32% |
CH
|
|
| 14.92% | -102.03% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Orient EuroPharma Co., Ltd.'s operating margin
What is Orient EuroPharma Co., Ltd.'s operating margin?
Orient EuroPharma Co., Ltd.'s operating margin is -7.36%, as of Nov 2026.
What was Orient EuroPharma Co., Ltd.'s operating margin in 2025?
In 2025, Orient EuroPharma Co., Ltd.'s operating margin was -6.76%, compared with 0.30% in 2024.
How has Orient EuroPharma Co., Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Orient EuroPharma Co., Ltd.'s operating margin was highest in 2020 (5.28%) and lowest in 2025 (-6.76%).
How does Orient EuroPharma Co., Ltd.'s operating margin compare with similar companies?
Orient EuroPharma Co., Ltd.'s operating margin (-7.36%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.